Rashmi Mehta

Statistics

Publications

Citations

882

H-Index

Active since

1993

Affiliations

Research Triangle Park Foundation(Current)

GlaxoSmithKline (United States)

GlaxoSmithKline (United Kingdom)

GlaxoSmithKline (Canada)

Age UK

Rashmi Mehta is an author at Research Triangle Park Foundation specializing in pharmacology, clinical pharmacology, and chronic obstructive pulmonary disease.

ORCID

Publications per year

1993–2023

Publications

Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD

Bartolomé R. Celli, Glenn Crater, Sally Kilbride et al. · CHEST Journal · 2014 · 155 citations

Medicine, Pharmacology, Pharmacotherapy +8

Umeclidinium in patients with COPD: a randomised, placebo-controlled study

Roopa Trivedi, Nathalie Richard, Rashmi Mehta et al. · European Respiratory Journal · 2013 · 92 citations · Full text

Medicine, Clinical Sciences, Pharmacology +17

A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD

James F. Donohue, Antonio Anzueto, Jean Brooks et al. · Respiratory Medicine · 2012 · 65 citations

Medicine, Clinical Sciences, Pharmacotherapy +7

Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients

Marc Decramer, François Maltais, Gregory Feldman et al. · Respiratory Physiology & Neurobiology · 2012 · 54 citations

Medicine, Pharmacology, Pharmacotherapy +12

Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Umeclidinium and Vilanterol Alone and in Combination: A Randomized Crossover Trial

Dennis Kelleher, Rashmi Mehta, Bernadette Jean-Francois et al. · PLoS ONE · 2012 · 43 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

1–5 of 27